Photocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan
Agreement Expands Photocure’s Hexvix®/Cysview® Franchise Footprint to over 30 Countries
Oslo, Norway January 26, 2021, Photocure ASA (PHO:OSE): The Bladder Cancer Company focused on delivering transformative solutions to improve the lives of bladder cancer patients, ...
100 NOK the last major resistance in the chart.
Ready to break out from Triangle formation.
Nice EMA 20 / 100 Bounce
Strong Analyst BUY consensus from DNB Markets, ABG, Norne etc.
Recent oversubscribed equity offerings done at 76 and 65,5 NOK after repurchasing global Hexvix ownership from Ipsen now securely in the money.
Recent newsflow:
13.08.2020 Photocure appoints Genotests as exclusive partner for Hexvix in Chile
08.07.2020 Photocure's partner Asieris Received China NMPA's Approval to Start a Global Phase III Clinical Trial for...
Largest owner in Photocure OSL:PHO apparently being forced to dump the whole position in the stock in the course of a few days, giving the stock extra momentum to the downside.
Updated list of shareholders show influx of US actors.
twitter.com
Patent covering the use of Blue Light Cystoscopy (BLC®) with Hexvix as neoadjuvant* therapy in the treatment of bladder cancer in patients who are scheduled for a cystectomy.
Early stage study results have shown an antitumor effect and induced systemic immune effects of hexaminolevulinate (HAL) and blue light in an orthotopic model of rat bladder cancer....
Recent news by OSL:PHO :
Randomized phase 3 study in Denmark demonstrates significant advantage in Bladder Cancer for Hexvix/Cysview blue light cystoscopy over standard white light variant:
photocure.com
At Q3 2019 Photocure reported continued record growth in the US as well as upfront payments from Chinese partner Asieris:
photocure.com
Further...
Photocure OSL:PHO presented Q3 numbers with top line numbers just a hint weaker than consensus, but with the strongest quarterly growth rate in deployed cystoscopes ever noted.
The stock is currently trading above earlier support, and a move through NOK 60 could trigger a strong BUY signal.
Q3 Report:
photocure.com
Q3 webcast in english with CEO Daniel...
Investors are eagerly awaiting Photocures OSL:PHO Q2 2019 report to get a more indepth description of the recently announced Cevira partnership deal.
Also key is the information about the current growth rate on Cysview sales in US.
NOK 60-64 is a key level of expected resistance, as it is where the share price peaked in 2018, while a negative reaction could...
Photocure $PHO.OL approaching relevant resistance levels and a breakout to the upside could easily be triggered as the market cap of the company is still low.
Recent Edison analysis quote:
" Phenomenal US growth
Q418 sales in the US increased 81% to NOK18.4m and are up 50% over the course of 2018 with a clear acceleration in the second half of the year. Unit...
Photocure $PHO.OL stock reacted with a correction after a overblown rally ahead of Q4 2018 report, but found firm footing and looks set to restart positive trend.
As mentioned in an earlier Idea ( ), the Q4 report represented a substantial risk for a downwards reaction after a recent surge in the share price.
At the new price level around NOK 41 the stock is much more attractively priced, and this could be the time to move in for new investors.
Photocure stock reacted with a heavy (overdone?) correction after the Q3 report, but has recovered nicely in later weeks.
As mentioned in an earlier TradingView analysis ( ), NOK 36 and downwards presented a very good buying opportunity, which culminated when the correction bottomed at NOK 32,5 which was a very solid resistance upwards for a long time.
Entry at...
